Opthea Limited (NASDAQ: OPT), an Australian biopharmaceutical company, commands attention within the healthcare sector for its pioneering work in the biotechnology industry. With a market capitalization of $583.1 million, Opthea is currently navigating an intriguing phase of its journey as it focuses on developing treatments for vision-threatening conditions like wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME).

The company’s flagship product, Sozinibercept, is currently in Phase 3 clinical trials for Wet AMD and Phase 2 for DME. These trials are pivotal for Opthea’s future, promising potential breakthroughs in treating these prevalent retinal diseases. However, investors should be mindful of the…